Randall Oliver, MD
Interventional Pain Medicine · Evansville, INNPI 1356393219
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.7% of the total across 125 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 11.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,312 and has fallen 54.3% since, to $599 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in IN, where the typical reported total is $4,157.
Across 125 payments — averaging $30.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stimwave Technologies Incorporated$443
- Nevro Corp.$390
- Amgen$368
- Medtronic$342
- Supernus Pharmaceuticals, Inc.$243
- Avadel CNS Pharmaceuticals, LLC$232
- plus $2K from 31 others
What the payments were for
- Consulting fees$2005%
- Food & beverage$3,55895%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stimwave Technologies Incorporated | 7 | $443 |
| Nevro Corp. | 4 | $390 |
| Amgen(2 entities) | 23 | $368 |
| Medtronic(3 entities) | 10 | $342 |
| Supernus Pharmaceuticals, Inc. | 7 | $243 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $232 |
| Upsher-smith Laboratories LLC | 9 | $220 |
| Curonix LLC | 1 | $142 |
| Vertos Medical, Inc. | 1 | $123 |
| Boston Scientific | 3 | $121 |
| MML US, Inc. | 2 | $91 |
| Avanir Pharmaceuticals, Inc. | 5 | $87 |
| Alkermes, Inc. | 2 | $85 |
| Globus Medical | 3 | $81 |
| Biodelivery Sciences International, Inc. | 5 | $75 |
| Indivior Inc. | 4 | $71 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $64 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Tris Pharma Inc | 3 | $53 |
| Scilex Pharmaceuticals Inc. | 2 | $42 |
| Teva Pharmaceuticals USA, Inc. | 3 | $41 |
| Abbott | 1 | $40 |
| Lilly USA, LLC | 3 | $39 |
| Sanofi-aventis U.S. LLC | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Stryker | 1 | $34 |
| Orexo US, Inc. | 2 | $28 |
| Pfizer | 2 | $27 |
| Novartis | 1 | $22 |
| Tersera Therapeutics LLC | 1 | $21 |
| Valinor Pharma, LLC | 1 | $21 |
| Si-bone, Inc. | 1 | $18 |
| Zyla Life Sciences, Inc. | 1 | $16 |
| AbbVie | 1 | $15 |
| Merck | 1 | $12 |
| AstraZeneca | 1 | $11 |
| MDD US Operations, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,758 in reported general payments places this provider in the 45th percentile of 68 interventional pain medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 85 | $15,308 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 14 | $10,944 |
| OxycontinOxycodone Hcl | 12 | $7,059 |
| MovantikNaloxegol Oxalate | 13 | $4,961 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $4,086 |
| Morphine Sulfate ErMorphine Sulfate | 103 | $3,425 |
| Gabapentin | 152 | $2,266 |
| Hydromorphone Hcl | 109 | $2,259 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 12 | $2,122 |
| Atomoxetine Hcl | 21 | $1,935 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 77 | $1,865 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 51 | $1,716 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 49 | $1,331 |
| Testosterone Cypionate | 19 | $1,273 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 71 | $1,223 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Orexo US, Inc.Zubsolv | $28 | $10,94414 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $35 | $4,08611 claims |
| Upsher-smith Laboratories LLCTopiramate | $220 | $21218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 68 interventional pain medicine providers in Indiana.
Other interventional pain medicine in Evansville
- Mahendra SanapatiEvansville$31K
- Mansoor KhanEvansville$5K
- Amy WalkerEvansville$1K
- Yusuf RashadaEvansville$339
- Joshua WellingtonCarmel$315K
- Joseph RutledgeLafayette$96K
- Orlando LandrumElkhart$34K
- Nikhil ShettyMunster$29K
- David GordonIndianapolis$28K
- Vinayak BelamkarIndianapolis$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.